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ABSTRACT
It is known that ultraviolet B (UVB) induces PPARγ ligand formation while loss of 
murine epidermal PPARγ (Pparg-/-epi) promotes UVB-induced apoptosis, inflammation, 
and carcinogenesis. PPARγ is known to suppress tumor necrosis factor-α (TNF-α) 
production. TNF-α is also known to promote UVB-induced inflammation, apoptosis, and 
immunosuppression. We show that Pparg-/-epi mice exhibit increased baseline TNF-α 
expression. Neutralizing Abs to TNF-α block the increased photo-inflammation and 
photo-toxicity that is observed in Pparg-/-epi mouse skin. Interestingly, the increase 
in UVB-induced apoptosis in Pparg-/-epi mice is not accompanied by a change in 
cyclobutane pyrimidine dimer clearance or in mutation burden. This suggests that loss 
of epidermal PPARγ does not result in a significant alteration in DNA repair capacity. 
However, loss of epidermal PPARγ results in marked immunosuppression using a 
contact hypersensitivity (CHS) model. This impaired CHS response was significantly 
alleviated using neutralizing TNF-α antibodies or loss of germline Tnf. In addition, the 
PPARγ agonist rosiglitazone reversed UVB-induced systemic immunosuppression (UV-
IS) as well as UV-induced growth of B16F10 melanoma tumor cells in syngeneic mice. 
Finally, increased B16F10 tumor growth was observed when injected subcutaneously 
into Pparg-/-epi mice. Thus, we provide novel evidence that epidermal PPARγ is 
important for cutaneous immune function and the acute photoresponse.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPAR) 
are ligand-activated nuclear transcription factors which 
exhibit binding affinity for a diverse range of bioactive 
lipid and xenobiotic agents [1]. Three different PPAR 
isotypes have been described (PPARα, PPARβ/δ, and 
PPARγ), each of which forms a heterodimer with 
the retinoid X-receptor (RXR). These heterodimeric 
complexes can then activate the transcription of target 
genes by binding to peroxisome proliferator response 
elements (PPRE). PPARs are also known to suppress 
the transcription of selected genes, particularly pro-
inflammatory gene products, through poorly understood 
ligand-dependent and ligand-independent transrepressive 
mechanisms (reviewed in [2]). The three PPARs exhibit 
different ligand specificities, tissue expression patterns 
and transcriptional targets, although all three isotypes are 
expressed in murine and human keratinocytes [1]. PPARγ 
is best known for its role in adipogenesis and insulin 
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sensitization. This has led to the use of synthetic PPARγ 
agonists (pioglitazone and rosiglitazone) as anti-diabetic 
agents [1]. PPARγ ligands have also been shown to have 
anti-cancer activity in tumor cell lines, in murine tumor 
models and in human clinical or epidemiological studies 
[3, 4].
Ultraviolet (UV) exposure from sunlight can be 
divided into UVA (320–400 nm), UVB (290–320 nm), 
and UVC (200-290 nm) [1]. However, UVC is filtered 
by the atmosphere and does not play a significant role 
in photobiology. Cutaneous carcinogenesis is primarily 
mediated by UVB exposure. We have shown that mice 
lacking epidermal PPARγ (Pparg-/-epi mice) are prone to 
increased skin tumor incidence and multiplicity following 
multiple UVB treatments [5]. In addition, mice lacking 
epidermal PPARγ or its heterodimerization partner 
(RXRα) and mice with germ-line deletion of one PPARγ 
allele exhibit enhanced chemical carcinogenesis [6, 7]. In 
addition to increased tumor formation, Pparg-/-epi mice 
exhibited increased sensitivity for photoinflammation, 
phototoxicity, epidermal hyperplasia and an increase in 
p53+ epidermal cells following chronic UVB treatments 
[5].
UVB exposure is immunosuppressive, acting to 
suppress Th-1 mediated delayed type hypersensitivity and 
contact hypersensitivity responses [8]. Studies in humans 
and mice indicate that UV-induced immunosuppression 
(UV-IS) plays an important role in photocarcinogenesis 
and anti-tumor immune responses [8, 9]. The ability of 
UV-IS to suppress anti-tumor immune responses is seen 
by the ability of UVB treatment to promote B16F10 tumor 
growth in C57BL/6 mice [9].
Various lines of evidence suggest that PPARγ 
may act to alter immune function. PPARγ expressed 
in various immune cells plays a role in modifying 
the immune function of these cells [10]. In addition, 
systemic PPARγ ligand treatment has been shown to 
inhibit allergic responses in the skin of mice and humans 
[11, 12]. Other studies suggest that PPARγ activation in 
non-immune cells may also regulate immune function 
through paracrine signaling. Transgenic mice expressing 
a dominant negative PPARγ in type II alveolar cells 
exhibited increased production of inflammatory mediators 
TNF-α, interleukin (IL)-1, and IL-6 that were necessary 
for an increase in immature myeloid cells and decreased 
T-cells within the lungs [13]. While it is unclear whether 
this led to an immunocompromised state in vivo, isolated 
immature pulmonary myeloid cells had the capacity to 
suppress T-cell activation in vitro [13].
DNA readily absorbs UVB, and this absorption can 
directly induce DNA lesions (cyclobutane pyrimidine 
dimer (CPD) or 6, 4-photoproduct formation) that can 
lead to DNA mutations [14]. That Pparg-/-epi mice exhibit 
a pronounced increase in sensitivity to UVB-induced 
apoptosis suggests a potential role for epidermal PPARγ in 
regulating UVB-induced mutation burden [5]. PPARs have 
been shown to regulate the expression of DNA damage 
response genes and oxidative stress [15, 16]. However, the 
ability of PPARs to regulate DNA repair and mutational 
events is largely unexplored.
Tumor necrosis factor alpha (TNF-α) is a primary 
inflammatory cytokine that is induced in keratinocytes 
by UV exposure and plays a key role in promoting 
photoinflammation, phototoxicity and UV-IS [17, 18]. 
Mice lacking either TNF-α or TNF receptors are also 
resistant to cutaneous chemical carcinogenesis [19, 20]. 
The ability of TNF-α to promote immune suppression 
has been attributed to multiple mechanisms, including 
depressed Langerhans cell migration and promotion 
of either myeloid-derived suppressor cell or mast cell 
accumulation [18, 21, 22]. TNF-α is initially produced 
as a 26 kDa transmembrane protein (tmTNF-α) that is 
cleaved to produce the 17 kDa soluble TNF-α (solTNF-α) 
[23]. Both tmTNF-α & solTNF-α have biological activity, 
with tmTNF-α acting as both a ligand and a receptor [24]. 
Importantly, while solTNF-α acts to promote inflammatory 
events, tmTNF-α is proposed to act to trigger resolution of 
the inflammatory response [25].
Given the well-known ability of PPARγ activation 
to suppress TNF-α expression in other cell types, as well 
as the known ability of TNF-α to mediate UVB-induced 
acute inflammation, apoptosis,and carcinogenesis, we 
examined whether the acute UVB responses that we have 
previously seen in Pparg-/-epi mice could be attributable 
to downstream TNF-α signaling. Given that cancer is 
ultimately dependent on mutational events, we also 
examined whether loss of epidermal Pparg altered UVB-
induced DNA damage and mutation frequency. Finally, we 
also sought to determine whether epidermal PPARγ acts to 
mediate cutaneous immune responses by examining both 
CHS and anti-tumor immune responses.
RESULTS
Pparg-/-epi mice exhibit an increase in TNF-α 
production
Given that PPARγ activation is known to 
suppress TNF-α production, we measured epidermal 
TNF-α expression in wildtype (WT) and Pparg-/-epi 
mice. We verified that TNF-α protein was increased by 
approximately 4-fold in protein lysates prepared from the 
epidermis of Pparg-/-epi mice (Figure 1A&1B). The size 
of the TNF-α protein seen by immunoblot is consistent 
with the full-length 26 kDa tmTNF-α. While our antibody 
reportedly detects the 17 kDa solTNF-α cleavage product, 
we did not observe a 17 kDa immunoreactive band 
consistent with solTNF-α in epidermal protein lysates (not 
shown).
UVB treatment is known to induce TNF-α production 
in the epidermis [17, 19]. We therefore examined how loss 
of epidermal Pparg alters TNF-α expression following an 
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acute UVB exposure. In Figure 1C , we show that untreated 
Pparg-/-epi mice express significantly higher levels of TNF-α 
transcripts relative to WT mice. A synergistic effect on TNF-α 
expression was noted when Pparg-/-epi mice were treated with 
UVB relative to UVB-treated WT mice. Finally, we examined 
TNF-α protein localization by immunohistochemistry 
(Figures 1D-1H). Epidermal TNF-α protein expression was 
observed in all mice, but was increased in non-UVB treated 
Pparg-/-epi epidermis relative to non-UVB treated WT mice. 
As with the RT-PCR studies, UVB-treated WT mice and 
non-UVB-treated Pparg-/-epi mice showed similar levels 
of TNF-α expression, while Pparg-/-epi mice treated with 
UVB showed the highest level of epidermal expression. 
Finally, consistent with our immunoblot data, UVB-treated 
WT mouse epidermis and basal or UVB-treated Pparg-/-epi 
mouse epidermis exhibits a characteristic cell membrane 
localization pattern that is consistent with a transmembrane 
form of TNF-α (Figures 1F-1H).
Figure 1: Increased TNF-α consistent with tmTNF-α is observed in Pparg-/-epi mice both prior to and after UVB 
irradiation. (A) Increased TNF-α protein is produced under normal physiologic conditions in the epidermis of Pparg-/-epi mice relative 
to WT mice. WT and Pparg-/-epi mice were euthanized and the epidermis was removed from the dorsal skin for protein extraction and 
TNF-α immunoblot. After stripping, a β-actin immunoblot was performed to assess loading. Representative immunoblots from epidermal 
preparations of two different WT and Pparg-/-epi mice are shown. Only an approximately 26 kDa protein was observed by anti-TNF-α 
immunoblot. A 17 kDa protein that would correspond to solTNF-α was not observed (not shown). (B) Quantitative assessment of TNF-α 
protein in epidermal lysates normalized to β-actin. TNF-α protein levels were normalized to β-actin. Mean & SEM, *, p<0.05; n= epidermal 
lysates from 5 mice/genotype. (C) TNF-α mRNA expression in WT and Pparg-/-epi mice. Mice were irradiated with 1500 J/m2 UVB. 
After 24 hours, the mice were euthanized, the skin excised, frozen in liquid N2, and the epidermis was scraped off for RNA extraction & 
quantitative RT-PCR (qRT-PCR). TNF-α expression in epidermal scrapings was normalized to 18 S rRNA. Mean and SEM, n=4-6 mice 
per experimental group. *, p<0.05; ***, p<0.001, 2-tailed t-test. (D-H) TNF-α protein expression localized to the epidermis following UVB 
irradiation is increased in Pparg-/-epi mice. Mouse skin was excised 24 hours after a 1500 J/m2 UVB treatment and formalin fixed and 
paraffin-embedded. Immunolabeling was then performed using an anti-TNF-α antibody (α-TNF). D.) Representative photomicrograph 
of a control in which staining was performed in the absence of the primary antibody. E-H.) Representative images of TNF-α expression 
within the epidermis of WT and Pparg-/-epi mice treated with or without UVB. Both UVB treatment and loss of epidermal Pparg were 
associated with an increase in staining consistent with localization to the cell membrane. All images are 400x and are representative of 
TNF-α immunolabeling performed on at least 3 different mice per treatment group.
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The enhanced acute edematogenic response to 
a single UVB exposure that is seen in Pparg-/-
epi mice is blocked by neutralizing anti-TNF-α 
antibodies
UVB-induced inflammation in mouse skin is 
initially assessed by the cutaneous edema response, 
which can be measured as a change in skin thickness at 
24 hours post-UVB treatment [26]. In Figure 2, we show 
that Pparg-/-epi mice exhibit a pronounced increase in UV-
induced skin thickness 24 hours after UVB irradiation [5]. 
Since TNF-α is a well-known pro-inflammatory mediator, 
we also examined whether increased TNF-α expression in 
Pparg-/-epi mice was involved in the increased sensitivity 
of Pparg-/-epi mice to photo-inflammation. In Figure 2, 
we also show that anti-TNF-α antibody treatment blocked 
the augmented UVB-induced inflammatory response in 
Pparg-/-epi mice.
The augmented apoptotic response to a single 
UVB exposure that is observed in Pparg-/-epi mice 
is also blocked by anti-TNF-α treatment
TNF-α augments UVB-induced apoptosis in 
keratinocytes [27]. We therefore examined whether 
anti-TNF-α neutralizing antibodies would suppress the 
augmented apoptosis that we have observed in Pparg-/-
epi mice 24 hours after UVB treatment [5]. As expected, 
we show that Pparg-/-epi mice treated with control 
IgG exhibit higher caspase 3/7 activities after UVB 
treatment relative to WT mice (Figure 3A). Caspases 3 
and 7 act downstream of both the intrinsic and extrinsic 
apoptotic pathways, while TNF-α can induce apoptosis 
through binding to the TNF receptor 1, thus activating 
caspase 8 in the extrinsic apoptosis pathway [28]. In 
Figure 3B, we show that UVB treatment induces an 
augmented activation of caspase 8 in Pparg-/-epi mice, 
and that this activation is blocked by anti-TNF-α 
antibodies.
Pparg-/-epi mice fail to exhibit alterations in UV-
induced CPD repair or mutation frequency or 
proliferative responses to UVB
Mice lacking epidermal PPARγ or its heterodimeric 
partner RXRα exhibit both enhanced cutanaeous 
carcinogenesis and an increase in UV-induced apoptosis 
(Figure 3 and [5, 29]). An increase in apoptosis might be 
indicative of increased DNA damage or an impaired DNA 
damage response. We therefore examined whether loss 
Figure 2: Neutralizing antibodies to TNF-α block the augmented increase in skin thickness that occurs following an 
acute UVB exposure of Pparg-/-epi mice. WT and Pparg-/-epi mice were injected intraperitoneally with 250 μg of anti-TNF-α antibodies 
(α-TNF) or an isotype control antibody (IgG). One day later, anesthetized mice were treated with or without 1500 J/m2 UVB. After 24 
hours, the mice were euthanized, the dorsal UVB-treated skin removed and snap frozen in liquid N2 for skin thickness measurements. Data 
is shown as the mean and SEM of the UVB-induced increase in skin thickness after subtracting non-UVB treated skin **, p<0.01, 2-tailed 
t-test. n=4-5 mice/group.
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of epidermal PPARγ promoted the formation of UVB-
induced DNA damage or mutation frequency. UVB-
induced mutations are largely thought to be mediated 
by the formation of CPD lesions in the DNA, which are 
cleared by the nucleotide excision repair (NER) pathway 
[14]. Using an EIA-based assay, we failed to observe any 
change in the rate of CPD clearance in Pparg-/-epi mice 
relative to WT mice (Figure 4A)(Supplementary Figure 
1A demonstrates the linearity of the EIA assay). We also 
failed to observe a significant difference in initial CPD 
lesions between WT and Pparg-/-epi mice (Supplementary 
Figure 1B). This strongly suggests that the NER process 
is not altered in Pparg-/-epi mice.
While clearance of CPD lesions is intact in Pparg-
/-epi mice, increased mutations can occur with normal 
CPD clearance, such as in individuals with Xeroderma 
pigmentosa variant (XPV) [30]. In addition, RXRα 
mice were shown to exhibit an increase in oxidative 
DNA damage following UV treatment, particularly in 
melanocytes [29]. Oxidized DNA lesions are not cleared 
by NER, but are repaired by base excision repair [31]. It 
is therefore possible that UVB-induced oxidative DNA 
damage could account for an increase in mutational events 
independent of CPD lesions. We therefore examined 
whether Pparg-/-epi mice exhibited a change in mutation 
frequency following an acute UVB treatment. To perform 
this analysis, we utilized Pparg-/-epi mice that were crossed 
with Big Blue® mice containing the λLIZ shuttle vector 
for mutation detection [32]. Using WT Big Blue mice and 
Pparg-/-epi Big Blue mice, we failed to find a significant 
difference in mutation frequency (MF) following UVB 
treatment (Figure 4B). The above data strongly suggests 
that the increased photocarcinogenesis that we have 
previously observed in Pparg-/-epi mice is not due to 
an increase in susceptibility to UVB-induced initiating 
mutational events.
Finally, an increase in epidermal proliferation 
was noted in non-tumor containing areas of Pparg-
/-epi mice relative to wildtype mice that had been 
treated chronically for 24 weeks with UVB [5]. This 
increase in epidermal hyperplasia following multiple 
UVB treatments could be due to the ability of PPARγ 
activation to directly suppress keratinocyte growth. If 
so, we reasoned that loss of epidermal PPARγ should 
result in an increase in the epidermal hyperplasia that 
is seen following a single UVB treatment [26]. In mice, 
epidermal hyperplasia peaks at approximately 72 hours 
post-UVB treatment [26]. In Figure 4C, the expression 
of the proliferation marker Ki67 within the epidermis 
of wildtype (WT) and Pparg-/-epi mice at baseline and 
72 hours after UVB treatment is shown. There was no 
appreciable difference in epidermal Ki67+ cells in WT 
Figure 3: Neutralizing antibodies to TNF-α block the augmented increase in UVB-induced apoptosis in Pparg-/-epi 
mice. WT and Pparg-/-epi mice were treated with IgG or anti-TNF-α antibodies, then treated with or without UVB as described in Figure 2. 
After 24 hours, the mice were euthanized and treated skin was snap frozen in liquid N2. Caspase 3/7 or caspase 8 activity was then assessed 
in epidermal scrapings. (A) Caspase 3/7 activity is shown for the UVB-treated animal groups after subtracting background activity from 
the relevant non-UVB treated groups. Results represent the mean and SEM from n=6, n=5, n=10, or n=5 mice for the WT+IgG, WT+α-
TNF, Pparg-/-epi+IgG, and Pparg-/-epi+α-TNF groups, respectively. (B) Caspase 8 activity is shown for the UVB-treated animal groups after 
subtracting background activity from the relevant non-UVB treated groups. Results represent the mean and SEM from n=3, n=3, n=4, or 
n=4 mice for the WT+IgG, WT+α-TNF, Pparg-/-epi+IgG, and Pparg-/-epi+α-TNF groups, respectively. *, p<0.05; **, p<0.01, 2-tailed t-test.
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or Pparg-/-epi mice in the absence of UVB. While UVB 
induced an increase in Ki67 immunolabeling at 72 
hours in both WT and Pparg-/-epi mice, the presence or 
absence of Pparg did not significantly affect the results. 
To verify that epidermal PPARγ status fails to impact 
the UVB-induced mitogenic effect, we utilized a second 
marker of epidermal proliferation (phospho-histone H3) 
(Figure 4D). Again, no significant difference was noted 
in the UVB-induced proliferative response from WT or 
Pparg-/-epi mice. We have also failed to demonstrate that 
PPARγ ligands alter the proliferation of primary human 
keratinocytes or mouse squamous cell carcinoma cells in 
vitro (data not shown). Thus, epidermal PPARγ does not 
likely play a significant direct role in mouse keratinocyte 
proliferative responses, either under basal conditions or 
following an acute UVB exposure.
Figure 4: Cyclobutane pyrimidine dimer (CPD) repair rates, mutation frequency, and epidermal hyperplasia are not 
altered in Pparg-/-epi mice following a single UV treatment. (A) UVB-induced CPD clearance is not altered in Pparg-/-epi mice. 
CPD clearance rates are shown for WT and Pparg-/-epi mice at 1, 24, and 48 hours after the treatment with a single 1500 J/m2 dose of UVB. 
Results are shown as the mean and SEM of the % of CPD lesions remaining relative to the 1 hour time point (n=5-7 mice per experimental 
group and time point). (B) UVB-induced mutation frequency (MF) is not altered by epidermal PPARγ status. Big Blue® mice backcrossed 
into the SKH-1 background were treated with 0, 100, 400-500 or 1500 J/m2 UVB. The mice were then euthanized 5 days later and the 
skin removed. Epidermal DNA was then utilized for lambda phage insertion and MF detection by plaque formation in a lawn of E. coli. 
After subtracting the average background (no UVB) MF, the mean and SEM of the MF (mutant plaques/total plaques x 105) is shown. The 
results represent data from n=1 mouse (100 J/m2), n=3 mice (400-500 J/m2) or n=4-5 mice (1500 J/m2) for each genotype. C&D.) Loss of 
epidermal Pparg does not promote epidermal hyperplasia following a single UVB treatment. WT and Pparg-/-epi mice were treated with or 
without a single dose of 1500 J/m2 UVB. At 72 hours, the mice were euthanized, the UVB-treated skin and non-UVB treated control skin 
was excised and Ki67 immunolabeling (C) or phospho-histone H3 (PHH3) immunolabeling (D) was performed. For Ki67 immunolabeling, 
the immunopositive cells are shown as a ratio of total epidermal cells. Mean and SEM, n=3-4 mice / group. For PHH3 immunolabeling, the 
results represent the number of PHH3+ epidermal cells per high power (400x) field (mean and SEM, n=4 mice / group).
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Contact hypersensitivity is impaired in Pparg-/-
epimice
UVB-induced TNF-α production has been shown to 
promote UV-IS [18]. We therefore examined whether CHS 
responses were altered in Pparg-/-epi mice. In Figure 5A , 
we show that Pparg-/-epi mice exhibit an approximately 
70% reduction in the CHS response to the contact allergen, 
2,4-dinitrofluorobenzene (DNFB). This CHS suppression 
was significantly greater than that observed for UVB 
treatment of WT SKH1 mice. The addition of UVB 
treatment to Pparg-/-epi mice resulted in no additional 
change to the impaired CHS response observed in non-
UVB treated Pparg-/-epi mice.
To determine whether the up-regulated TNF-α 
production observed in Pparg-/-epi mice could be playing a 
role in the impaired CHS response observed in these mice, 
we treated WT and Pparg-/-epimice with neutralizing anti-
TNF-α antibodies and again assessed CHS responses using 
the strategy outlined in Figure 5B. In Figure 5C, we show 
that anti-TNF-α treatment had no significant effect on the 
CHS response in WT mice, but significantly reversed the 
immunosuppression seen in Pparg-/-epi mice. Finally, we 
determined whether loss of germline Tnf would reverse the 
impaired CHS response in Pparg-/-epi mice. We therefore 
generated Pparg-/-epi x Tnf-/- crosses. In Figure 5D, we 
show that loss of Tnf alone resulted in a reduction in the 
CHS response. This reduction in CHS responses was 
not as pronounced as that observed in Pparg-/-epi mice. 
Importantly, the combined loss of Tnf in Pparg-/-epi mice 
reversed the impaired CHS response to that observed with 
loss of Tnf alone.
Rosiglitazone treatment blocks systemic UVB-
induced immunosuppression (UV-IS) and UVB-
induced B16F10 tumor growth
We next examined whether the PPARγ agonist 
rosiglitazone (Rosig) could reverse UV-IS. Control mice 
treated with a high dose of UVB at a site distant from 
the site of DNFB sensitization exhibited a reduction in 
ear inflammation following subsequent DNFB challenge 
(Figure 6A). Rosiglitazone treatment alone had no effect 
on the CHS response in non-UVB treated mice. However, 
rosiglitazone blocked the ability of UVB treatment to 
suppress the CHS response.
Following the transplant of B16F10 melanoma 
tumor cells into syngeneic mice, we have demonstrated 
that UV-IS promotes the growth of the transplanted tumors 
[9]. In Figure 6B, we show that rosiglitazone treatment 
blocks the ability of UVB to promote B16F10 tumor 
growth. Since B16F10 cells express PPARγ [33], it is 
possible that rosiglitazone treatment suppressed B16F10 
tumor growth through direct effects on the tumor cells. 
We therefore determined whether rosiglitazone affected 
B16F10 tumor cell growth in vitro. We did not observe 
a significant decrease in B16F10 tumor cell growth 
at concentrations up to 1 μm, well above the binding 
affinity for rosiglitazone for PPARγ (EC
50
 = 23 nM )[34] 
(Figure 6C). We also examined whether the growth of 
subcutaneous B16F10 tumors were altered in Pparg-/-epi 
mice derived in the C57BL/6 background (C57.Pparg-
/-epi mice). We observed a nearly 2-fold increase in 
tumor growth in C57.Pparg-/-epi mice relative to tumors 
transplanted into wildtype C57BL/6 mice.
DISCUSSION
We have previously shown that mice lacking 
epidermal PPARγ are highly susceptible to UVB-induced 
photoinflammation, phototoxicity and photocarcinogenesis 
[5]. The two major findings from this current study are 
that TNF-α plays a key role in the ability of epidermal 
PPARγ to alter UVB-induced acute inflammation and 
apoptosis and that loss of epidermal PPARγ also results in 
suppression of normal contact hypersensitivity responses 
while the PPARγ agonist rosiglitazone reverses UVB-
induced immune suppression. We also provide evidence 
that PPARγ-dependent suppression of basal TNF-α 
production serves as a major mechanism for this observed 
immunosuppressive activity. Thus, we propose that 
PPARγ-dependent suppression of TNF-α signaling plays 
a key mechanistic role in the acute photo-response and 
cutaneous immune function. The potential importance of 
our findings to cutaneous neoplasia is illustrated by the 
ability of the PPARγ ligand rosiglitazone to reverse both 
UVB-induced impairment in CHS responses as well as 
UVB-induced B16F10 tumor growth. Finally, we show 
that B16F10 melanoma tumor growth is enhanced in 
syngeneic C57.Pparg-/-epi mice, indicating that loss of 
epidermal PPARγ acts through indirect mechanisms to 
regulate tumor growth.
PPARγ activation is known to suppress 
inflammatory signaling and TNF-α production in other cell 
types [2, 10, 13]. TNF-α production is known to mediate 
UVB-induced inflammatory responses [17, 18]. We now 
show that TNF-α expression is upregulated in Pparg-/-epi 
mice and that TNF-α neutralizing antibodies suppress the 
augmented photo-inflammatory response that is observed 
in Pparg-/-epi mice. We also found that increased epidermal 
TNF-α expression is observed in Pparg-/-epi mice under 
basal conditions (no UVB). This basal increase presumably 
represents a sustained, rather than transient, elevation of 
TNF-α. While no specific stimuli was introduced, basal 
TNF-α expression likely occurs in response to everyday 
cutaneous stressors (e.g. sloughing of skin due to contact 
with other mice and the cage environment or exposure 
to commensal flora). In addition, we provide evidence 
that the transmembrane form of TNF-α (tmTNF-α) is 
upregulated in the epidermis of Pparg-/-epi mice. Since 
Pparg-/-epi mice exhibit increased photocarcinogenesis, 
a potential role for tmTNF-α as a downstream mediator 
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of epidermal PPARγ is interesting given that studies 
using Tnf, Tnfr1 or Tnfr2 knockout mice or mice treated 
with anti-TNF-α antibodies suggest that TNF-α acts 
to promote cutaneous carcinogenesis in mice [19, 20]. 
Figure 5: Pparg-/-epi mice exhibit a marked defect in the contact hypersensitivity (CHS) response that is not affected 
by UVB exposure but is suppressed by anti-TNF-α neutralizing antibodies. (A) Pparg-/-epi mice are immunosuppressed using 
a CHS model. WT and Pparg-/-epi mice were treated with or without UVB (7500 J/m2) on the dorsal skin at a site distant to where the mice 
were initially sensitized to the hapten dinitrofluorobenzene (DNFB). Initial DNFB sensitization of the mice occurred five days after UVB 
treatment. Nine days after the initial DNFB sensitization, ear thickness was measured and DNFB was applied to one ear while the other 
ear was treated with vehicle. The change in ear thickness was assessed 24 hours after DNFB challenge and is plotted as the change in ear 
thickness after subtracting the thickness of the contralateral ear treated with vehicle alone. Results represent the change in ear thickness 
measurements as a percent of non-UVB treated control SKH1 wildtype mice. Results represent the mean ± SEM for 6 non-UVB treated 
and 4 UVB-treated mice per genotype. (B) Timeline for neutralizing anti-TNF-a studies. WT SKH1 and Pparg-/-epi mice were injected 
intraperitoneally (ip) with 250 μg of either anti-TNF-α or isotype control on days -1, 0, 2 and 5. On day 0, the dorsal skin of the mice were 
sensitized with 0.5% DNFB. CHS responses to DNFB challenge were assessed 9 days later by measuring ear thickness and applying DNFB 
to the left ear and vehicle to the right ear. Ear thickness was re-measured 1 day later. (C) Anti-TNF-α antibody treatment (anti-TNF-α) 
reversed the impaired CHS response observed in Pparg-/-epi mice, but has no effect on CHS responses in WT mice. Mice were treated as 
described in Figure 5C. Results represent the percent change in ear thickness measurements compared to wildtype SKH1 mice treated with 
control IgG alone. Mean and SEM for n=5-6 mice per experimental group. (D) Germline loss of Tnf (Tnf-/-) partially reverses the impaired 
CHS response in Pparg-/-epi mice. WT mice, Tnf-/- mice, Pparg-/-epi mice, and Pparg-/-epi x Tnf-/- double knockout mice were sensitized 
with DNFB. After 7 days, a DNFB challenge was applied to the left ear and ear thickness was measured. CHS responses (as a percentage 
of WT response) were assessed. Mean and SEM, n=8 (WT), n=16 (Pparg-/-epi), n=6 (Tnf-/-), and n=10 (Pparg-/-epi X Tnf-/-). *, p<0.05; 
**, p<0.01; ***, p<0.001, 2-tailed t-test. In the absence of any stimulation, there was no significant difference in baseline ear thickness 
measurements between WT, Pparg-/-epi, Tnf-/-, or Pparg-/-epi X Tnf-/- mice (0.247 ± 0.019 mm, n=18; vs 0.251 ± 0.024 mm, n=27 vs. 0.235 
± 0.014, n=10 vs 0.249 ± 0.012, n=14; respectively).
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However, there has been an inconsistent and controversial 
correlation between anti-TNF-α therapies and increased 
risk for non-melanoma skin cancer in humans [35–37]. 
While neutralizing anti-TNF-α antibodies were thought to 
Figure 6: Rosiglitazone (Rosig) reverses UVB-induced immunosuppression and UVB-induced B16F10 tumor growth 
while intradermal B16F10 tumor growth is increased in mice lacking epidermal Pparg. (A) Rosig treatment reverses UVB-
induced immunosuppression (UV-IS). SKH1 mice were treated with Rosig or normal water for 10 days prior to treatment of the shaved 
dorsal epidermis with/without 7500 J/m2 UVB to a site distant from DNFB sensitization. Rosig treatment was maintained throughout the 
experiment. Following DNFB sensitization, CHS responses to DNFB reapplication to non-UVB treated ears were measured 9 days later as 
in Figure 5. Results are shown as a percentage change from non-UVB/non-Rosig treated control mice (No UVB) and are depicted as the 
mean and SEM (n=7 mice / group). ***, p<0.001; 2-tailed t-test. (B) Rosig treatment reverses UVB-induced B16F10 tumor growth. C57BL6 
mice were introduced to Rosig or water for 10 days prior to tumor cell injection. Just prior to tumor cell injection, and on days 6 and 12 
thereafter, anesthetized mice were treated with/without 5000 J/m2 UVB at a site distant from tumor cell injection. B16F10 melanoma tumor 
cells (5x105) were injected subcutaneously into the rear hindlimbs and tumor growth monitored. Mean and SEM shown (n=12/group). 
Tumor growth was significantly increased in UVB treated mice relative to non-UVB treated (Sham) or UVB treated mice that were also 
treated with Rosig (UVB+Rosig). ***, p<0.001; 2-way ANOVA. (C) Rosig does not significantly alter B16F10 tumor cell growth in vitro. 
B16F10 tumor cells were grown in the presence of vehicle (0) or increasing concentrations of Rosig. After 48 hours, cell proliferation was 
assessed by quantitating viable cells by MTT assay. The results represent the mean and SEM of n=5 separate assays done in quadruplicate 
wells. (D) Subcutaneous B16F10 tumors grow significantly faster in syngeneic mice lacking epidermal Pparg (C57.Pparg-/-epi mice). 
C57BL6 mice with epidermal specific deletion of Pparg were generated (C57. Pparg-/-epi mice) to allow for syngeneic tumor growth 
studies. B16F10 tumor cells (5x104) were injected into the hindlimbs of WT or C57.Pparg-/-epi mice and tumor size was monitored. At day 
18, the mean tumor size in C57.Pparg-/-epi mice was 2.07-fold greater than that observed in WT mice (mean ± SEM of 590.9 ± 334 and 
1221.9 ± 677.6 for 10 tumors in WT and 8 tumors in C57.Pparg-/-epi mice respectively). ***, p<0.001, 2-way ANOVA,.
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act primarily by blocking solTNF-α activity, more recent 
evidence suggests that some effects that are elicited by 
these agents may occur through interaction with tmTNF-α 
[24]. It is therefore possible that the ability of these 
therapies to suppress or promote carcinogenesis may be 
related to the relative ability of specific anti-TNF-α agents 
to block tmTNF-α versus solTNF-α signaling.
Increased apoptosis is commonly thought to 
primarily protect against mutational events and subsequent 
tumorigenesis. The heightened sensitivity of Pparg-/-
epi mice to increased phototoxicity therefore suggests a 
possible role for epidermal PPARγ in regulating UVB-
induced DNA damage or repair. UVB-induced DNA 
damage within the epidermis is also thought to initiate 
the signaling cascade that leads to local UV-IS [38]. 
However, the inverse correlation between apoptosis and 
mutational events is context dependent: This protection 
is dependent on appropriate coordination between cell 
cycle arrest, apoptotic signaling and DNA repair processes 
[39, 40]. Our data indicates that cyclobutane pyrimidine 
dimer (CPD) mutation clearance and overall mutation 
frequency are not altered in Pparg-/-epi mice. It therefore 
seems unlikely that PPARγ plays a key role in regulating 
DNA repair in keratinocytes. Our conclusion is supported 
by a study showing that mice lacking epidermal RXRɑ, 
which partners with PPARγ to regulate PPARγ-dependent 
transcriptional activity, exhibit increased UVB-induced 
apoptosis coupled to normal CPD clearance [29]. A 
limitation of our studies was that we only examined the 
effects of a single UVB exposure on CPD clearance 
and mutation frequency. Given the marked increase in 
photocarcinogenesis observed in Pparg-/-epi mice, we 
cannot exclude the possibility that loss of keratinocyte 
PPARγ plays a role in the long-term adaptive response of 
the skin to repetitive UVB exposures. In addition, given 
the increased apoptosis in the setting of normal DNA 
damage repair and mutation frequency, it seems likely 
that PPARγ plays a role in apoptotic signaling that is 
downstream of the initial DNA damage repair process. 
It is possible that this is mediated by increased TNF-α, 
as TNF-α synergizes with UVB to induce apoptosis in 
keratinocytes [27].
Various studies have shown that activation of PPARγ 
within various cells of the immune system can alter their 
function [41–44]. Additional pharmacologic studies have 
suggested a role for PPARγ in regulating adaptive immune 
function [45]. However, these studies do not rule out off-
target pharmacologic effects [45]. Our studies add to 
these previous results by conclusively demonstrating that 
PPARγ expression within epithelial cells can indirectly 
regulate immune function using the well-established 
in vivo contact hypersensitivity (CHS) assay of T-cell 
mediated immunity. We observed an approximately 70% 
reduction in CHS responses in Pparg-/-epi mice. To put this 
into perspective, it is useful to compare this reduction to 
that observed for agents that are well known to suppress 
CHS: UVB, platelet activating factor, and histamine 
suppress CHS responses by approximately 30-50% [46–
48].
Our studies also show that anti-TNF-α neutralizing 
antibodies reverse the CHS defect observed in Pparg-
/-epi mice, but the antibodies had no effect on WT mice. 
Treatment with anti-TNF-α Abs, or loss of Tnf or TNFR-
2, but not TNFR-1, results in a significant blockade of 
local UV-IS [18, 49–51]. However, the ability of anti-
TNF-α neutralizing antibody treatment to suppress basal 
CHS responses is inconsistently seen in the literature 
[50, 52, 53]. Differences between studies on the basal 
CHS response in the presence of neutralizing anti-TNF-α 
antibodies could be due to the mouse genetic background, 
or possibly differences in the dosing, timing, and 
specificity of the antibody reagents.
Finally, the impaired CHS responses seen in Pparg-
/-epi mice is reversed in Pparg-/-epi mice crossed with 
Tnf-/- mice. As anti-TNF-α antibodies generally block 
both solTNF-α and tmTNF-α signaling [24], our studies 
are unable to determine whether solTNF-α or tmTNF-α 
signaling (or both) are necessary for the impaired CHS 
defect in Pparg-/-epi mice. However, it is possible that 
increased tmTNF-α mediates the immunosuppression 
seen in Pparg-/-epi mice: tmTNF-α is proposed to act 
through TNFR2 that is thought to be primarily involved 
in impaired CHS responses [21, 24, 25]. However, we 
cannot exclude the possibility that solTNF-α plays a key 
role as well since diffusion of this mediator may have 
reduced its presence within the epidermis. Future work is 
also necessary to determine whether epidermal TNF-α or 
TNF-α expressed by other cells is the primary determinant 
of the impaired CHS response in Pparg-/-epi mice.
In addition to the defective CHS responses observed 
in Pparg-/-epi mice, we also demonstrate that treatment with 
Rosig blocks UV-IS. UVB-induced immunosuppression 
is thought to play a key role in photocarcinogenesis and 
is associated with increased B16F10 melanoma tumor 
growth [9]. Our demonstration that Rosig treatment is 
able to completely block the ability of UVB treatments 
to promote B16F10 tumor growth suggests that this is 
due to the ability of Rosig to block UV-IS. However, it 
is also possible that increased inflammation in the tumor 
microenvironment may have also contributed to the 
increased tumor cell growth. In addition to the ability of 
Rosig treatment to block UV-induced tumor growth, we 
also show that B16F10 tumor cells grow faster in Pparg-/-
epi mice. This clearly demonstrates that epidermal PPARγ 
plays an important indirect role in B16F10 tumor growth. 
Since Pparg-/-epi mice also have a profound defect in CHS 
responses, we speculate that increased tumor growth in 
Pparg-/-epi mice is secondary to a defect in anti-tumor 
immune responses. However, additional work is necessary 
to further define the mechanisms and downstream effector 
cells that mediate the increased tumor growth in Pparg-/-
epi mice.
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In conclusion, our current data indicates that epidermal 
PPARγ plays a robust role in modulating cutaneous 
inflammation, cutaneous immune responses and potentially 
anti-tumor immune surveillance. We also demonstrate that 
the ability of epidermal PPARγ to alter the photoresponse is 
largely dependent on TNF-α production. As a major organ 
exposed to environmental oxygen, the epidermis is constantly 
exposed to oxidative stress. Since endogenous PPARγ ligand 
production occurs non-enzymatically through lipid oxidation 
[54, 55], we therefore speculate that PPARγ may function to 
initiate a protective signaling pathway that serves to suppress 
inappropriately exuberant inflammatory responses and to 
promote robust immune system monitoring of oxidatively 
damaged cells within the epidermis or dermis.
MATERIALS AND METHODS
Reagents and chemicals
All chemicals were obtained from Sigma-Aldrich 
(St. Louis, MO, USA) unless indicated otherwise. 
Rosiglitazone maleate was obtained from Tecoland Corp 
(Irvine, CA, USA). Caspase-3/7 and caspase-8 activity 
assays were purchased from Promega (Caspase-Glo® 8 
and Caspase-Glo® 3/7; Madison, WI, USA).
Animals
The generation of wildtype (WT) and Pparg-/-epi 
mice in the SKH1 background were previously described 
[5]. For mutation studies, Big Blue® mice expressing the 
λLIZ shuttle vector in the C57Bl/6 background (Agilent 
Technologies, La Jolla, CA) were backcrossed with SKH-1 
mice (Charles Rivers, Wilmington, MA) for 6 generations. 
These mice were then crossed with Pparg-/-epi mice in the 
SKH-1 background to generate Pparg-/-epi mice containing 
the λLIZ transgene. Wildtype (WT) sibling controls lacked 
the K14-Cre transgene. To generate Pparg-/-epi mice with 
germline loss of Tnf (Pparg-/-epi X Tnf-/-), B6.129S-Tnftm1Gkl/J 
mice (Stock Number 005540, The Jackson Laboratory, Bar 
Harbor, ME) were backcrossed into the SKH-1 background 
for 6 generations prior to crossing with Pparg-/-epi mice. For 
B16F10 tumor studies, B6.129-Ppargtm2Rev/J mice (Stock 
Number: 004584, The Jackson Laboratory) were crossed 
with B6N.Cg-Tg(KRT14-cre)1Amc/J mice (Stock Number 
018964, The Jackson Laboratory) to generate epidermal-
specific PPARγ knockout mice in the C57BL/6 background 
(C57.Pparg-/-epi mice). Mice were housed under specific 
pathogen-free conditions at the Indiana University School 
of Medicine. The protocols were approved by the Indiana 
University School of Medicine Institutional Animal Care and 
Use Committee (IACUC).
Acute UVB-induced apoptosis and inflammation
To assess the photoinflammatory and phototoxic 
responses, anesthetized mice were treated with 1500 
J/m2 of UVB using FS40 lamps and the epidermis was 
removed after 24 hours for caspase 3 activity assessment 
as previously described [5]. Caspase 8 activity assays 
were performed essentially as described for the caspase 
3 activity assays using Caspase-Glo® reagents specific 
for caspase 8. To assess the acute inflammatory edema 
response, skin thickness was assessed as previously 
described [26].
TNF-α qRT-PCR
Quantitative RT-PCR (qRT-PCR) was performed 
from RNA prepared from curetted epidermal scrapings of 
mouse skin using primers specific to murine Tnf transcript 
and 18S ribosomal RNA (RT2 qPCR Primer, Qiagen, 
Valencia, CA). Results were normalized using the 2-ΔΔCT 
method [56].
TNF-α immunoblot
Mice were sacrificed by CO2 asphyxiation and a 
section of the dorsal skin was excised. The epidermis was 
isolated by thermolysin treatment using a modification 
of a protocol described by Ikehata et al [57]. Briefly, the 
skin was scraped to remove fat and muscle, and then was 
floated epidermal side up in 0.5ml/ml Thermolysin (sigma 
Alsdrich) in buffer (10 mM HEPES pH 7.4, 142mM 
NaCl, 6.7 mM KCl, 1 mM CaCl2), incubated at 37
oC for 
45 minutes. The epidermis was removed, snap frozen in 
liquid nitrogen, and stored at -80oC. Frozen skin samples 
were fragmented, suspended in modified RIPA buffer, 
(150 mM NaCl, 20 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 
mM EGTA, 1% Nonidet P40, 1% Sodium Deoxycholate, 
0.1% SDS, 1 mM Na3VO4, 10 mM NaF, 0.2 mM Pefabloc, 
complete protease inhibitor (Roche Life Science). After 
further homogenization, the samples were then centrifuged 
and the supernatant was quantified for protein by BCA 
assay. 50 μg samples were run on SDS-PAGE and 
immunoblots performed with anti-TNF-α (clone D2D4, 
Cell Signaling Technology), followed by stripping and 
immunoblotting with anti-β-actin (clone AC-15, Sigma 
Aldrich).
TNF-α immunohistochemistry
Immunolocalization of TNF-α protein expression in 
skin was performed on formalin-fixed paraffin-embedded 
sections. After deparaffinization, heat-induced antigen 
retrieval was performed in Borg Decloaker, RTU solution 
(Biocare Medical, Concord, CA, USA) in a pressure 
cooker for 20 minutes. Following non-specific protein and 
Fc-receptor blocking, immunohistochemical staining was 
performed using a polyclonal goat anti-TNF-α antibody 
(diluted 1:100; SC-1350, Santa Cruz Biotechnology, 
Dallas, TX), followed by donkey anti-goat-horseradish 
peroxidase secondary (1:200; SC-2020, Santa Cruz) and 
3,3’-diaminobenzidine (DAB) chromagen detection.
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Contact hypersensitivity studies
Contact hypersensitivity studies utilized a 
modification of our previously described methodology 
[48]. Wildtype (WT), Pparg-/-epi, Tnf-/-, and double 
knockout (Pparg-/-epi XTnf-/- cross) in the SKH1 
background were used for these studies. For rosiglitazone 
studies, mice were treated with rosiglitazone maleate (40 
μg/ml) in water or regular water ad libitum for 10 days 
prior to UVB treatment and were maintained on oral 
rosiglitazone treatment throughout the experiments. The 
estimated daily intake was 8 mg/kg/day. Oral rosiglitazone 
has been shown to be systemically active in mice at doses 
of 3-8 mg/kg/day [58, 59]. An approximately 2.5 × 2.5-
cm area of the distal back skin of these mice were treated 
with 7500 J/m2 UVB or were left untreated. After 5 days, 
mice were sensitized with topical 25 μl 0.5% DNFB in 
acetone:olive oil (4:1, v/v) on an area of the dorsal skin 
approximately 2.5 cm distant from the UVB-irradiated 
site. After 7 or 9 days, ear thickness was measured using 
a digital caliper and then 10 μl 0.5% DNFB was painted 
on the dorsal sides of one ear, whereas the other ear was 
painted with vehicle. After 24 hours, an elicitation reaction 
was measured by measuring the ear thickness as a final 
read out. Finally, post-DNFB ear thickness was subtracted 
from pre-DNFB ear thickness of the contralateral ear 
treated with vehicle alone (measured 24 hours earlier).
Anti-TNF-α neutralization studies
WT and Pparg-/-epi mice were injected 
intraperitoneally (ip) with 250 μg of either anti-TNF-α 
antibodies (clone XT3.11 InVivoMAb) or an isotype 
control antibody (rat IgG1) (both from Bio X Cell, West 
Lebanon, NH, USA). Injections were performed as 
indicated in the figure legends.
B16F10 growth in vitro
B16F0 cells were maintained in RPMI 1640 
(Mediatech) supplemented with 10% fetal bovine serum 
(Invitrogen) and 100 μg/ml penicillin and streptomycin 
(Invitrogen). B16F10 cells were plated onto a 96-well 
plate at 1250 cells/well. The next day, the media was 
replaced with media containing either vehicle (ethanol) 
or rosiglitazone maleate at concentrations ranging 
from 1-1000 nM. After 48 hours of growth, viable cells 
were quantitated by incubating the cells with 12 mM 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) per the manufacturer’s instructions 
(Vybrant® MTT Cell Proliferation Assay Kit, 
ThermoFisher Scientific, Waltham, MA, USA).
B16F10 tumor growth in vivo
B16F10 tumor growth in vivo was performed in either 
C57BL/6 mice lacking epidermal Pparg (C57.Pparg-/-epi) 
or sibling controls lacking the K14-Cre allele (WT).Ten 
days prior to tumor cell implantation (day -10), treatment 
with either rosiglitazone or water was initiated as described 
above for the contact hypersensitivity studies. On day 0, 
the dorsal skin of C57BL/6 mice were shaved, and 5x105 
B16F10 cells were inoculated subcutaneously into the right 
flank of each mouse as described [9]. For UVB studies, 
mice were treated with 5000 J/m2 UVB on day 0, 6 and 
12 on a 2.5 x 2.5 cm area of shaved dorsal skin which was 
approximately 3 cm away from the shielded tumor injection 
site. Tumor growth was measured daily with calipers as 
described [9]. When 5x105 cells are used per injection, 
spontaneous tumor ulceration frequently occurs after 12 
days. Invariably, this tumor ulceration is quickly followed 
by evidence of shock (unpublished observations). This 
required euthanasia per our approved protocol and limited 
our observation period for the UVB studies to 12 days. For 
this reason, when we examined B16F10 tumor cell growth 
in WT and C57.Pparg-/-epi mice, we utilized a modification 
of this approach by implanting 10-fold less cells (5x104). 
This allowed us to extend the period of time in which tumor 
growth was observed to 18 days.
Cyclobutane pyrimidine dimer (CPD) clearance
WT and Pparg-/-epi mice were treated with 1500 J/
m2 UVB. At 1, 24 & 48 hrs, the mice were euthanized, 
the irradiated skin was removed and snap frozen, then 
the epidermis removed by scraping. After DNA isolation, 
the DNA was diluted to a concentration of 4 μg/ml in 
0.1x PBS (pH7.4). For a standard curve, salmon sperm 
DNA (0.5 mg/ml in 0.1x PBS, pH7.4) was treated with 
increasing doses of UVB (0, 312.5, 625, 1250, 2500, or 
5000 J/m2), then diluted to 4 μg/ml as above. Standard 
curve DNA and murine epidermal DNA were treated at 
95˚C for 10 min, rapidly placed on ice, and 50 μl of DNA 
or PBS alone was added to the wells of a protamine sulfate 
treated microwell plate. For protamine sulfate treatment, 
0.003% protamine sulfate in H2O was prepared and 50 μl 
added to each well of 96-well plate. The plates were then 
allowed to dry overnight at 37˚C prior to the addition of 
DNA. After the addition of denatured DNA, the samples 
were allowed to dry completely by incubating at 37˚C. 
The plates were washed with PBS containing 0.05% 
Tween 20 (PBS-T), then blocked using CAS-Block™ 
(Life Technologies) diluted 1/25 in PBS containing 
0.01 g/ml bovine serum albumin, and 0.5 μg/ml salmon 
sperm DNA. After incubating 30 min at 37˚C, the plates 
were washed with PBS-T, and anti-thymine dimer HRP 
conjugate (Clone KTM53; Kamiya Biomedical, Seattle, 
WA, USA), diluted 1:2300 in PBS was added. After 1 hr 
at 37˚C, the plates were washed and LumiGLO® substrate 
(Cell Signaling Technology, Danvers, MA, USA) was 
added. Following luminescence detection, CPD levels in 
UV treated mouse epidermal DNA were then calculated as 
J/m2 equivalents based on the standard curve.
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Mutation frequency
Big Blue® mice or related lacZ mice (MutaMouse) 
have been successfully used to study both UVA & UVB-
induced mutagenesis [60, 61]. For mutation studies, 
WT and Pparg-/-epi mice expressing the λLIZ transgene 
were anesthetized and treated with increasing doses of 
UVB. Control mice were not UVB treated. Five days 
later we euthanized the mice and excised the treated skin 
for epidermal DNA isolation. We waited 5 days before 
euthanasia to allow for both complete repair of CPD 
lesions and for clearance of mutations in non-cancer 
causing suprabasal cells through epidermal turnover 
(epidermal transit time = 3-5 days for hairless mouse 
epidermis) [62, 63]. For DNA isolation, we separated the 
epidermis from the subcutaneous tissue using thermolysin 
as described above. Cells of the epidermis were isolated 
by trypsinization in 0.25% trypsin and the cellular nuclei 
DNA was isolated using the RecoverEase™ DNA Isolation 
Kit (Agilent Technologies). Samples were dialyzed 
in TE buffer using G Biosciences Tube-O-Dialyzer. 
The mutation frequency was determined using Agilent 
Transpack Packaging Extract and λSelect-cII Mutation 
Detection System for Big Blue Rodents.
Statistical analysis
Group comparisons are shown as mean and standard 
error and were analyzed for statistical significance as 
detailed in each figure legend using Graphpad Prism 5.0 
(Graphpad Software, Inc., San Diego, CA, USA).
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